{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T18:09:38Z","timestamp":1769105378426,"version":"3.49.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Alexion, Celgene, Novartis, Otsuka"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.leukres.2019.106170","type":"journal-article","created":{"date-parts":[[2019,6,12]],"date-time":"2019-06-12T15:15:11Z","timestamp":1560352511000},"page":"106170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Delayed time from RBC transfusion dependence to first cardiac event in lower IPSS risk MDS patients receiving iron chelation therapy"],"prefix":"10.1016","volume":"83","author":[{"given":"Colleen A.C.","family":"Wong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7899-2025","authenticated-orcid":false,"given":"Heather A.","family":"Leitch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.leukres.2019.106170_bib0005","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.mayocp.2015.04.001","article-title":"Myelodysplastic syndromes: diagnosis and treatment","volume":"90","author":"Steensma","year":"2015","journal-title":"Mayo Clinic proceedings. [Review]"},{"issue":"2","key":"10.1016\/j.leukres.2019.106170_bib0010","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2141.1982.tb08475.x","article-title":"Proposals for the classification of the myelodysplastic syndromes","volume":"51","author":"Bennett","year":"1982","journal-title":"Br. J. Haematol."},{"issue":"1\u20132","key":"10.1016\/j.leukres.2019.106170_bib0015","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.cbi.2009.10.009","article-title":"The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasms","volume":"184","author":"Vardiman","year":"2010","journal-title":"Chem Biol Interact. [Review]."},{"key":"10.1016\/j.leukres.2019.106170_bib0020","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.leukres.2017.02.008","article-title":"New proposals of the WHO working group (2016) for the diagnosis of myelodysplastic syndromes (MDS): characteristics of refined MDS types","volume":"57","author":"Strupp","year":"2017","journal-title":"Leuk. Res."},{"issue":"6","key":"10.1016\/j.leukres.2019.106170_bib0025","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood."},{"issue":"12","key":"10.1016\/j.leukres.2019.106170_bib0030","first-page":"2454","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood. [Research Support, Non-U.S. Gov\u2019t]."},{"issue":"8","key":"10.1016\/j.leukres.2019.106170_bib0035","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1002\/cncr.22570","article-title":"Myelodysplastic syndromes: incidence and survival in the United States","volume":"109","author":"Ma","year":"2007","journal-title":"Cancer."},{"issue":"10","key":"10.1016\/j.leukres.2019.106170_bib0040","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.leukres.2005.03.004","article-title":"Hemoglobin level threshold for cardiac remodeling and quality of life in myelodysplastic syndrome","volume":"29","author":"Oliva","year":"2005","journal-title":"Leuk. Res."},{"issue":"30","key":"10.1016\/j.leukres.2019.106170_bib0045","doi-asserted-by":"crossref","first-page":"7594","DOI":"10.1200\/JCO.2005.01.7038","article-title":"Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making","volume":"23","author":"Malcovati","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"November (21)","key":"10.1016\/j.leukres.2019.106170_bib0050","article-title":"48-month update on survival and AML transformation in a 600-patient registry of lower-risk MDS patients","volume":"122","author":"Lyons","year":"2013","journal-title":"Blood. [Annual Meeting Abstracts]."},{"issue":"1","key":"10.1016\/j.leukres.2019.106170_bib0055","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/bjh.14825","article-title":"Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis","volume":"179","author":"Leitch","year":"2017","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2019.106170_bib0060","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.leukres.2018.02.005","article-title":"Iron overload in lower international prognostic scoring system risk patients with myelodysplastic syndrome receiving red blood cell transfusions: relation to infections and possible benefit of iron chelation therapy","volume":"67","author":"Wong","year":"2018","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2019.106170_bib0065","article-title":"Impact of treatment with iron chelation therapy in lower-risk MDS patients participating in the European Leukemianet MDS (EUMDS) Registry","author":"Hoeks","year":"2017","journal-title":"Blood. [ASH Annual Meeting Abstracts]."},{"issue":"5","key":"10.1016\/j.leukres.2019.106170_bib0070","first-page":"779","article-title":"Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications","volume":"94","author":"Remacha","year":"2015","journal-title":"Annals of hematology. [Multicenter Study Research Support, Non-U.S. Gov\u2019t]."},{"issue":"21","key":"10.1016\/j.leukres.2019.106170_bib0075","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.2800.2800","article-title":"24-month analysis of the impact of chelation on clinical outcomes in a 600 patient registry of lower-risk MDS patients","volume":"118","author":"Lyons","year":"2011","journal-title":"Blood."},{"issue":"6","key":"10.1016\/j.leukres.2019.106170_bib0080","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1600-0609.2007.00842.x","article-title":"Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity\/mortality","volume":"78","author":"Takatoku","year":"2007","journal-title":"Eur. J. Haematol."},{"issue":"17","key":"10.1016\/j.leukres.2019.106170_bib0085","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1200\/JCO.2009.25.2395","article-title":"Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries","volume":"28","author":"Goldberg","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.leukres.2019.106170_bib0090","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.V95.4.1229.004k32_1229_1236","article-title":"Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia","volume":"95","author":"Davis","year":"2000","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.leukres.2019.106170_bib0095","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1182\/blood-2003-08-2841","article-title":"Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major","volume":"104","author":"Davis","year":"2004","journal-title":"Blood."},{"issue":"7","key":"10.1016\/j.leukres.2019.106170_bib0100","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.leukres.2009.12.004","article-title":"Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A Multicenter Study by the GFM","volume":"34","author":"Rose","year":"2010","journal-title":"Leuk. Res."},{"issue":"5","key":"10.1016\/j.leukres.2019.106170_bib0105","first-page":"557","article-title":"Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes","volume":"38","author":"Delforge","year":"2014","journal-title":"Leukemia Research. [Multicenter Study Research Support, Non-U.S. Gov\u2019t]."},{"issue":"4","key":"10.1016\/j.leukres.2019.106170_bib0110","first-page":"327","article-title":"Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes","volume":"4","author":"Zeidan","year":"2015","journal-title":"J Comp Eff Res. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov\u2019t]."},{"key":"10.1016\/j.leukres.2019.106170_bib0115","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-111134","article-title":"Safety and efficacy, including event-free survival, of deferasirox versus placebo in iron-overloaded patients with low- and int-1-risk myelodysplastic syndromes (MDS): outcomes from the randomized, double-blind Telesto study","author":"Angelucci","year":"2018","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.leukres.2019.106170_bib0120","first-page":"1","volume":"90","author":"Gattermann","year":"2011","journal-title":"Iron overload in MDS-pathophysiology, diagnosis, and complications. Annals of hematology. [Review]."},{"issue":"5","key":"10.1016\/j.leukres.2019.106170_bib0125","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0022-2828(03)00072-5","article-title":"Differential accumulation of non-transferrin-bound iron by cardiac myocytes and fibroblasts","volume":"35","author":"Liu","year":"2003","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"23","key":"10.1016\/j.leukres.2019.106170_bib0130","doi-asserted-by":"crossref","first-page":"16046","DOI":"10.1016\/S0021-9258(17)33971-6","article-title":"Uptake of non-transferrin-bound iron by both reductive and nonreductive processes is modulated by intracellular iron","volume":"269","author":"Randell","year":"1994","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.leukres.2019.106170_bib0135","first-page":"36","article-title":"Effects of iron loading on uptake, speciation, and chelation of iron in cultured myocardial cells","volume":"122","author":"Parkes","year":"1993","journal-title":"J. Lab. Clin. Med."},{"issue":"1\u20132","key":"10.1016\/j.leukres.2019.106170_bib0140","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/03630260701726491","article-title":"Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone","volume":"32","author":"Kolnagou","year":"2008","journal-title":"Hemoglobin. [Case Reports]."},{"key":"10.1016\/j.leukres.2019.106170_bib0145","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.199.199","article-title":"Low-iron diet and chelation therapy rescue severe atherosclerosis associated with high circulating iron levels","author":"Vinchi","year":"2016","journal-title":"Blood."},{"key":"10.1016\/j.leukres.2019.106170_bib0150","first-page":"94","article-title":"Atherogenesis and iron: from epidemiology to cellular level","volume":"5","author":"Vinchi","year":"2014","journal-title":"Front Pharmacol. [Review]"},{"issue":"11","key":"10.1016\/j.leukres.2019.106170_bib0155","first-page":"1380","article-title":"Improved survival with iron chelation therapy for red blood cell transfusion dependent lower IPSS risk MDS may be more significant in patients with a non-RARS diagnosis","volume":"36","author":"Leitch","year":"2012","journal-title":"Leukemia Research. [Research Support, Non-U.S. Gov\u2019t]."},{"issue":"3","key":"10.1016\/j.leukres.2019.106170_bib0160","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3816\/CLK.2008.n.026","article-title":"Improved survival in patients with myelodysplastic syndrome receiving iron chelation therapy","volume":"2","author":"Leitch","year":"2008","journal-title":"Clin. Leuk."},{"issue":"8","key":"10.1016\/j.leukres.2019.106170_bib0165","first-page":"1067","article-title":"Improved survival in MDS patients receiving iron chelation therapy - a matched pair analysis of 188 patients from the Dusseldorf MDS registry","volume":"36","author":"Neukirchen","year":"2012","journal-title":"Leukemia Research. [Evaluation Studies Research Support, Non-U.S. Gov\u2019t]."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521261930116X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521261930116X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T14:59:34Z","timestamp":1663685974000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014521261930116X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":33,"alternative-id":["S014521261930116X"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2019.106170","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Delayed time from RBC transfusion dependence to first cardiac event in lower IPSS risk MDS patients receiving iron chelation therapy","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2019.106170","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106170"}}